Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The proteasome serves as the catalytic core of the Ubiquitin (Ub) protein degradation pathway and has become an intriguing target in drug development and cancer therapy. Successful pharmacologic inhibition of the proteasome with the small molecule bortezomib led to US Food and Drug Administration (FDA) regulatory approval for the treatment of mantle cell lymphoma and multiple myeloma (MM) and has been extended to a steadily increasing number of clinical trials to assess effi cacy and safety in other hematologic malignances and solid tumors.
Citation:
Driscoll JJ, Burris J, Annunziata CM (2010) Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy. J Cell Sci Ther 1:101.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi